Article Information
PMID
Published By
Print ISSN
0250-7005
Online ISSN
1791-7530
History
- Received March 7, 2007
- Accepted May 16, 2007
- Published online July 1, 2007.
Copyright & Usage
Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
Author Information
- BRIAN HIGGINS1,
- KENNETH KOLINSKY1,
- MICHAEL LINN2,
- VIOLETA ADAMES2,
- YU-E ZHANG3,
- CARLOS MOISA4,
- UTE DUGAN4,
- DAVID HEIMBROOK1 and
- KATHRYN PACKMAN1
- 1Department of Discovery Oncology, Hoffmann-La Roche Inc., Nutley, NJ 07110, U.S.A.
- 2Department of Non-Clinical Drug Safety, Hoffmann-La Roche Inc., Nutley, NJ 07110, U.S.A.
- 3Department of Pharmaceutical and Analytical R&D, Hoffmann-La Roche Inc., Nutley, NJ 07110, U.S.A.
- 4Department of Medical Affairs Oncology, Hoffmann-La Roche Inc., Nutley, NJ 07110, U.S.A.
- Correspondence to: Brian Higgins, 340 Kingsland Street, Nutley, NJ 07110, U.S.A. Tel: +1 973 235 6303, Fax: +1 973 235 6185, e-mail: brian_x.higgins{at}roche.com
Statistics from Altmetric.com
Cited By...
In this issue
Jump to section
Related Articles
Cited By...
- Resolution of Spatial and Temporal Heterogeneity in Bevacizumab-Treated Breast Tumors by Eigenspectra Multispectral Optoacoustic Tomography
- Capecitabine Monotherapy: Review of Studies in First-Line HER-2-Negative Metastatic Breast Cancer
- Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First-Line Treatment for HER-2-positive Locally Recurrent or Metastatic Breast Cancer
- Activity of the Kinesin Spindle Protein Inhibitor Ispinesib (SB-715992) in Models of Breast Cancer
- Preclinical Profile of a Potent {gamma}-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties
- In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models
- Novel Regimens of Capecitabine Alone and Combined with Irinotecan and Bevacizumab in Colorectal Cancer Xenografts